Literature DB >> 9610710

The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies.

T J Ruescher1, A Sodeifi, S J Scrivani, L B Kaban, S T Sonis.   

Abstract

BACKGROUND: Antibacterial prophylaxis with quinolone antibiotics has resulted in an increase in streptococcal infections among bone marrow transplantation (BMT) recipients with myelosuppression. Oral ulceration (mucositis), which frequently occurs as a consequence of chemotherapy, has been implicated as a significant portal of entry for streptococci. The objectives of this study were to confirm the correlation between mucositis and streptococcal bacteremia, determine the risk associated with this correlation, and evaluate the impact of mucositis and streptococcal bacteremia on hospital course and costs associated with autologous BMT.
METHODS: This was a retrospective, case-control study in which the charts of autologous BMT recipients treated for hematologic malignancies between 1990 and 1996 were reviewed. Twenty-four patients were identified who met the criteria of autologous BMT; their blood cultures confirmed (x2) alpha-hemolytic streptococcal sepsis. A control group of 45 without positive cultures was matched by gender, age, diagnosis, and treatment to the study group.
RESULTS: The results confirm that ulcerative mucositis is a significant risk factor for alpha-hemolytic streptococcal bacteremia among autologous BMT patients. Of the 24 patients with bacteremia, 15 of 24 (62%) had ulcerative mucositis, compared with 16 of 45 (36%) of patients in the control population (P < 0.05). Patients with ulcerative mucositis were found to be three times as likely to develop alpha-hemolytic streptococcal bacteremia as those without ulcerative mucositis (odds ratio=3.02). Both independently and as a cofactor associated with bacteremia, mucositis adversely affected the length of hospital stay (LOS). Of all the patients studied, those with oral ulcerations had a LOS of 34 days, compared with 29 days for patients without oral ulcerations (P < 0.05). Of patients in the study group, those with oral ulcerations stayed in the hospital 6 days longer than patients without oral ulcerations (40 days vs. 34 days, P < 0.05).
CONCLUSIONS: Oral ulcerative mucositis is a significant, common, and important risk factor for alpha-hemolytic streptococcal bacteremia in BMT recipients with myelosuppression; it results in longer hospital stay and increased costs.

Entities:  

Mesh:

Year:  1998        PMID: 9610710

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

1.  Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.

Authors:  J Radocha; P Paterová; A Zavřelová; B Víšek; F Gabalec; H Žemličková; P Žák
Journal:  Folia Microbiol (Praha)       Date:  2017-08-03       Impact factor: 2.099

2.  The gene expression sequence of radiated mucosa in an animal mucositis model.

Authors:  S T Sonis; J Scherer; S Phelan; C A Lucey; J E Barron; K E O'Donnell; R J Brennan; H Pan; P Busse; J D Haley
Journal:  Cell Prolif       Date:  2002-08       Impact factor: 6.831

3.  Traumeel S in preventing and treating mucositis in young patients undergoing SCT: a report of the Children's Oncology Group.

Authors:  S F Sencer; T Zhou; L S Freedman; J A Ives; Z Chen; D Wall; M L Nieder; S A Grupp; L C Yu; I Sahdev; W B Jonas; J D Wallace; M Oberbaum
Journal:  Bone Marrow Transplant       Date:  2012-04-16       Impact factor: 5.483

4.  LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.

Authors:  Navin Khattry; Alok Gupta; Reetu Jain; Adwaita Gore; Ravi Thippeswamy; Nandish Jeevangi; Sadhana Kannan; Reena Nair; Tapan Saikia
Journal:  Int J Hematol       Date:  2016-01-04       Impact factor: 2.490

5.  Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.

Authors:  Matin M Imanguli; Jane C Atkinson; Kristen E Harvey; Gerard T Hoehn; Ok Hee Ryu; Tianxia Wu; Albert Kingman; A John Barrett; Michael R Bishop; Richard W Childs; Daniel H Fowler; Steven Z Pavletic; Thomas C Hart
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

6.  Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.

Authors:  A H E Herbers; W J F M van der Velden; A F J de Haan; J P Donnelly; N M A Blijlevens
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

Review 7.  Host-Microbiome Cross-talk in Oral Mucositis.

Authors:  R M Vasconcelos; N Sanfilippo; B J Paster; A R Kerr; Y Li; L Ramalho; E L Queiroz; B Smith; S T Sonis; P M Corby
Journal:  J Dent Res       Date:  2016-04-06       Impact factor: 6.116

8.  Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

Authors:  Ajay K Nooka; Heather R Johnson; Jonathan L Kaufman; Christopher R Flowers; Amelia Langston; Conor Steuer; Michael Graiser; Zahir Ali; Nishi N Shah; Sravanti Rangaraju; Dana Nickleach; Jingjing Gao; Sagar Lonial; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-06       Impact factor: 5.742

Review 9.  Supportive cryotherapy: a review from head to toe.

Authors:  Kunal C Kadakia; Shaina A Rozell; Anish A Butala; Charles L Loprinzi
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

Review 10.  Management of oral mucositis in patients who have cancer.

Authors:  Rajesh V Lalla; Stephen T Sonis; Douglas E Peterson
Journal:  Dent Clin North Am       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.